At FDA, doctors urge black -box warning about hormone therapy for menopause

When midwife Joann Pinkerton Recently spoke about a Panel Food and Drug Administration, she has not chopped words.

“Please stop the damage to women,” she said.

Pinkerton states that the Black Box -warning labels of the FDA about hormone replacement therapies make women reluctant to take medicines that can be beneficial for the treatment of the symptoms of menopause.

Pinkerton was One of 12 Doctors-many of them experts in obstetrics and the health of women who asked the FDA to remove the warning labels for vaginal low dose of estrogen treatment.

The drug is usually prescribed to women to reduce the symptoms of menopause or perimenopause. In contrast to other systemic hormone therapy treatments that are absorbed by the entire body, it is supplied locally – by a patch, a cream or a ring.

The Black Box -warning is the strongest safety label that the FDA can apply a prescribed medicine. And Pinkerton and others claim that such a warning for a low dose of estrogen treatment is not necessary.

The drug is often prescribed to prevent or tackle symptoms related to the menopause, including frequent urinary tract infections, vaginal dryness and pain during sexual intercourse.

“The warning in the framework is not supported by science,” says Pinkerton. “It exaggerates the risk.”

Pinkerton described a recent patient with such symptoms, for whom she had written a recipe. She brings out the tube, “and there is a warning: endometrial cancer, cardiovascular disorders, probable dementia and breast cancer. And she looks at it, her partner or husband looks at it and she throw it in the waste,” says Pinkerton.

A pendulum swing to HRT

The consensus of the medical institution on the safety of hormone treatment for menopause has changed dramatically in recent decades. In 2002, researchers partially stopped a large study About the health of women – The Women’s Health Initiative – Out of concern that hormone therapy was associated with an increased risk of cancer and strokes. Breast cancer was a special concern. Since then, researchers and doctors have established that the risk of cancer was overestimated.

Treatments and best practices in the neighborhood when they need to prescribe hormone therapy and which medicines have evolved in recent decades.

Many doctors in the health of women have argued for this change for years without success. Recent studies suggest that the cancer risks of some hormone therapies are quite low and there are considerable benefits for women who go through the menopause. This is a problem with pets for Dr. Marty Makary – The current FDA commissioner. Makary is a surgeon, not a midwife. He raised the panel.

“Fifty million women have not received the incredible potential health benefits of hormone replacement therapy,” Makary said when opening comments in the panel, “because of medical dogma.”

Makary said that his own family could have benefited from this treatment when it got out of favor at the medical institution.

“One of those women was my mother,” he said, “who went through the perimenopause around that time.”

Midwives and gynecologists who were interviewed for this story agreed that they would like to see that the Black Box label is being removed for a low dose of vaginal estrogen treatments that entail a lower risk of cancer.

“I will usually make a joke about, hey, we have been working for many years to try to have that black box warning removed, but you know how slowly government affairs can last,” said Dr. Monicwho regularly prescribes such treatments to its patients. Christmas is an OB-Gyn who is also the associated medical director The Menopause Society.

Christmas, however, expressed reluctantly about the removal of labels for Systemic estrogen, Who has another risk profile for cancer.

“For the vast majority of people, the risk is low, even for systemic hormone therapy,” said Christmas, “but it’s not zero.”

Christmas said that the black box -warning doctors and patients can cause the necessary conversations about the risks and Benefits of such medicines.

The FDA panel was primarily aimed at low dose of estrogen, but Makary also hinted when removing the label for systemic therapy, stating the benefits as suggested in some studies for reduced risk of osteoporosisAmong other things.

“We all want to learn from you,” Makary told the panel members, “help us, thinking about what should be done here at the FDA.”

“This was theater, not scientific evaluation”

The panel was a deviation from the typical decision -making at the FDA.

“This was theater, this was not a scientific evaluation,” said Adriane Fugh-Berman,A professor in pharmacology at the University of Georgetown. Fugh-Berman is skeptical about deleting Such labels and point out that the FDA usually has a more rigorous process to inform these types of changes.

“That process is undermined and distorted,” she said.

(Fugh-Berman has worked as a paid expert witness in lawsuits against pharmaceutical companies accused of persuading the benefits of hormone therapy and contributions to breast cancer.)

FDA decision-making often includes a period of public input. Committees are appointed to study issues and make recommendations. Fugh-Berman said she would rather have seen a period of public commentary, as well as an expert committee with a broader range of experts such as epidemiologists, oncologists and public health experts.

Representatives of the FDA did not respond to a request for comments on this story or comment on future steps in a potential process to remove the warnings from recipes.

At least one midwife celebrated the increased attention for this issue, even if it came through an unconventional process.

“I was very happy,” said Rachel Rubin, a urologist With a specialty in sexual medicine. Rubin was also a panel member. “The fact that the head of the FDA wants to talk about this subject is extraordinary and something we have all dreamed about,” she says.

Rubin acknowledged the departure of the level of strictness that the FDA usually keeps.

“Were there any voices? Of course,” she says. But given this opportunity, she said, it is worth appearing for “fighting for something you’ve been fighting against for decades.”

Ob-Gyn Monica Christmas would not say if she thought that the composition of the panel should have been different or the process more rigorous. But she expressed concern that enthusiasm for the hormonal treatment for menopause can be to darken the necessary risk-benefit analysis that patients and doctors should make when considering these medicines.

“Hormone therapy has become synonymous with the menopause,” she says. And she warns that women have to exclude other problems before they jump to hormone therapy.

“It’s almost like:” Oh, I’m in the menopause, “says Christmas,” I should be to have hormone therapy for all these magical or mystical benefits. “